These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1422972)

  • 1. Effects of a short course of oral phosphate treatment on serum parathyroid hormone(1-84) and biochemical markers of bone turnover: a dose-response study.
    Brixen K; Nielsen HK; Charles P; Mosekilde L
    Calcif Tissue Int; 1992 Oct; 51(4):276-81. PubMed ID: 1422972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis.
    Horowitz M; Wishart JM; Need AG; Morris HA; Nordin BE
    Clin Endocrinol (Oxf); 1993 Dec; 39(6):649-55. PubMed ID: 8287582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
    Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
    J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intravenous EDTA treatment on serum parathyroid hormone (1-84) and biochemical markers of bone turnover.
    Guldager B; Brixen KT; Jørgensen SJ; Nielsen HK; Mosekilde L; Jelnes R
    Dan Med Bull; 1993 Nov; 40(5):627-30. PubMed ID: 8299406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of intermittent slow-release sodium fluoride and continuous calcium citrate therapy on calcitropic hormones, biochemical markers of bone metabolism, and blood chemistry in postmenopausal osteoporosis.
    Zerwekh JE; Padalino P; Pak CY
    Calcif Tissue Int; 1997 Oct; 61(4):272-8. PubMed ID: 9312196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients.
    Hodsman AB; Fraher LJ
    Bone Miner; 1990 May; 9(2):137-52. PubMed ID: 2161692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered bone and mineral metabolism in patients receiving imatinib mesylate.
    Berman E; Nicolaides M; Maki RG; Fleisher M; Chanel S; Scheu K; Wilson BA; Heller G; Sauter NP
    N Engl J Med; 2006 May; 354(19):2006-13. PubMed ID: 16687713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis.
    Schlosser K; Scigalla P
    Scand J Clin Lab Invest Suppl; 1997; 227():21-8. PubMed ID: 9127465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.
    Rejnmark L; Buus NH; Vestergaard P; Heickendorff L; Andreasen F; Larsen ML; Mosekilde L
    J Bone Miner Res; 2004 May; 19(5):737-44. PubMed ID: 15068496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consumption of a high calcium mineral water lowers biochemical indices of bone remodeling in postmenopausal women with low calcium intake.
    Meunier PJ; Jenvrin C; Munoz F; de la Gueronnière V; Garnero P; Menz M
    Osteoporos Int; 2005 Oct; 16(10):1203-9. PubMed ID: 15744450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism.
    Beshyah SA; Thomas E; Kyd P; Sharp P; Fairney A; Johnston DG
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):383-91. PubMed ID: 8187303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased serum osteocalcin levels in patients with postmenopausal osteoporosis.
    Pietschmann P; Resch H; Krexner E; Woloszczuk W; Willvonseder R
    Acta Med Austriaca; 1991; 18(5):114-6. PubMed ID: 1796722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study.
    Hansen TB; Brixen K; Vahl N; Jørgensen JO; Christiansen JS; Mosekilde L; Hagen C
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3352-9. PubMed ID: 8784096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal responsiveness to endogenous parathyroid hormone in postmenopausal osteoporosis.
    Ebeling PR; Jones JD; Burritt MF; Duerson CR; Lane AW; Hassager C; Kumar R; Riggs BL
    J Clin Endocrinol Metab; 1992 Oct; 75(4):1033-8. PubMed ID: 1400868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.